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INTRODUCTION:  
Oral drug delivery is the most widely utilized route of 
administration among all the routes that have been 
explored for systemic delivery of drugs via 
pharmaceutical products of different dosage form. The 
objective of any drug delivery system is to afford a 
therapeutic amount of drug to the proper site of action in 
the body to attain promptly, and then maintain the 
desired drug concentration1. An ideal drug delivery 
system (DDS) should aid in the optimization of drug 
therapy by delivering an appropriate amount to the 
intended site and at a desired rate. Hence, the DDS 
should deliver the drug at a rate dictated by the needs of 
the body over the period of treatment.  
Advances in oral controlled-release technology are 
attributed to the development of novel biocompatible and 
machineries that allow preparation of novel design 
dosage forms in a reproducible manner. The main oral 
drug-delivery approaches that have survived through the 
ages are as follows2,3: 
● Coating technology using various polymers for coating 
tablets, nonpareil sugar beads, and granules 
● Matrix systems made of swellable or nonswellable 
polymers 
● Slowly eroding devices 
● Osmotically controlled devices. 
One of the most feasible approaches for achieving a 
prolonged and predictable drug delivery profile in the GI 
tract is to control the gastric residence time (GRT). 
Dosage form with a prolonged GRT, that is gastro 
retentive dosage forms (GRDFs), will provide us with 
new and important therapeutic options
4
.  GRDFs extend 
significantly the period of time over which the drugs may 
be released. Thus, they not only prolong dosing intervals, 
but also increase patient’s compliance beyond the level 
of existing controlled release dosage forms. 
Gastric retention will provide advantages such as the 
delivery of drugs with narrow absorption window in the 
small intestinal region. Also, longer residence time in the 
stomach could be advantageous for local action in the 
upper part of the small intestine, for example treatment 
of peptic ulcer disease. Furthermore, improve bio 
availability is expected for drugs that are absorbed 
readily upon release in the GI tract. These drugs can be 
delivered ideally by slow release from the stomach5. 
Cephalexin is in a group of drugs called cephalosporin 
antibiotics and is used to fight bacteria in the body. It 
works by interfering with the bacteria's cell wall 
formation, causing it to rupture, and killing the 
bacteria6,7,8. It has good absorption in GIT, low pKa, 
which remained unionized in the stomach for better 
absorption and it has a half life of 0.5-1-2 hours. 
Cephalexin is used to treat infections caused by bacteria, 
including upper respiratory infections, ear infections, 
skin infections, and urinary tract infections9,10,11. 
The aim of the present study was not only preparing 
Cephalexin floating system but also to release the drug in 
the controlled manner, therefore the maximum drug 
release is maintained at desired site. The effect of 
different polymers and the effect of amount of polymers 
was investigated in the formulation to monitor the 
sustained release effect respectively. 
MATERIALS & METHODS: 
Materials: Cephalexin (drug) was obtained as a gift 
sample from A.P. drugs control office Hyd, india, 
remaining all the excipients were procured from SD Fine 
Chemicals Pvt. Limited. 
Method: Direct compression method. 
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Preparation of floating tablets of cephalexin: 
The composition of different formulations was shown in 
Table no.1. The powder mixture containing drug, 
controlled release polymers as per the formulae and 
MCC  used as the diluent, sodium bicarbonate as 
effervescent agent were mixed thoroughly. The blend 
was lubricated with magnesium stearate for 3-5 mins and 
talc was added as glidant. The mixed blend was then 
compressed into tablets by direct compression method 
using 12 mm punches on a sixteen station rotary tablet 
punching machine. 
 
Table 1: Formulation development of Cephalexin floating tablets: 
Formulation 
(mg) 
F1 F2 F3 F4 F5 F6 F7 F8 
Drug 250 250 250 250 250 250 250 250 
HPMC K4M 100 125 150 100 100 100 100 100 
Xanthan gum --- --- --- 50 --- --- --- --- 
Guar gum --- --- --- --- 50 --- --- --- 
Karaya gum --- --- --- --- --- 50 --- --- 
Sodium CMC --- --- --- --- --- --- 50 --- 
Ethyl cellulose --- --- --- --- --- --- --- 50 
Sod.Bicarbonate 66 66 66 66 66 66 66 66 
Citric acid 20 20 20 20 20 20 20 20 
Talc 05 05 05 05 05 05 05 05 
Mg. stearate 05 05 05 05 05 05 05 05 
MCC 104 79 54 54 54 54 54 54 
 
     Formulation 
(mg) 
F9 F10 F11 F12 F13 F14 F15 F16 
Drug 250 250 250 250 250 250 250 250 
HPMC K100 M 50 75 100 65 65 65 65 65 
Xanthan gum --- --- --- 35 --- --- --- --- 
Guar gum --- --- --- --- 35 --- --- --- 
Karaya gum --- --- --- --- --- 35 --- --- 
Sodium CMC --- --- --- --- --- --- 35 --- 
Ethyl cellulose --- --- --- --- --- --- --- 35 
Sod.Bicarbonate 66 66 66 66 66 66 66 66 
Citric acid 20 20 20 20 20 20 20 20 
Talc 05 05 05 05 05 05 05 05 
Mg. stearate 05 05 05 05 05 05 05 05 
MCC 154 129 104 104 104 104 104 104 
Total Tablet weight in all formulation is 550 mg. 
EVALUATION OF GRANULES: (PRE-
COMPRESSION PARAMETERS) 
Angle of Repose: 
The angle of repose was determined by the funnel 
method. The accurately weighed powder was taken in a 
funnel. The height of the funnel was adjusted in such a 
way that the tip of the funnel just touched the apex of the 
heap of the powder. The powder was allowed to flow 
through the funnel freely onto the surface. The diameter 
of the powder cone was measured. 
The angle of repose was then calculated by measuring 
the height and radius of the heap of granules formed. 
tan θ = h/r 
θ = tan-1 (h/r) 
Where, θ = angle of repose 
h = height of the heap 
r = radius of the heap 
 
Bulk Density (BD): 
An accurately weighed powder blend from each 
formula was lightly shaken to break any agglomerates 
formed and it was introduced in to a measuring cylinder. 
The volume occupied by the powder was measured 
which gave bulk volume. The loose bulk density (BD) of 
powder blends was determined using the following 
formula. 
Bulk density = Total weight of powder / Total volume of 
powder 
 
Tapped bulk density (TBD): 
An accurately weighed powder blend from each 
formula was lightly shaken to break any agglomerates 
formed and it was introduced into a measuring cylinder. 
The measuring cylinder was tapped until no further 
change in volume was noted which gave the tapped 
volume. The tapped bulk densities (TBD) of powder 
blends were determined using the following formula. 
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Tapped bulk density = Total weight of powder / Total 
volume of tapped powder 
Hausner’s Ratio: 
    It indicates the flow properties of the powder and is 
measured by the ratio of tapped density to the bulk 
density  
H = Dt / Db 
where       H is the Hausner’s ratio  ,                                                                                                  
                 Dt is the tapped density of the powder and   Db 
is the bulk density of the powder. 
Hausner’s ratio less than 1.25 indicates good flow while 
greater than 1.5 indicates poor flow. 
CARR’S Compressibility Index: It is a simple index 
that can be determined on small quantities of powder. 
The compressibility indices of the formulation blends 
were determined using following Carr’s compressibility 
index formula. 
 
Carr’s Compressibility Index (%) =    
       Tapped bulk density – Bulk density     × 100 
              Tapped bulk density 
 
EVALUATION OF TABLETS: (POST 
COMPRESSION PARAMETERS) 
The prepared tablets were evaluated for their parameters 
such as weight variation, thickness, hardness, friability, 
drug content, swelling index, in vitro buoyancy, in vitro 
drug release studies. 
Weight Variation: 
Twenty tablets were randomly selected from each batch 
and individually weighed. The average weight and 
standard deviation of 20 tablets were calculated. Then 
each batch passes the test for weight variation  if not 
more than two of the individual tablet deviate from the 
average weight by more than the percentage. 
Hardness: 
Hardness indicates the ability of a tablet to withstand 
mechanical shocks while handling. The hardness of the 
tablets was determined using Monsanto hardness tester. 
It was expressed in kg/cm2. Ten tablets of each 
formulation were randomly picked and hardness of the 
tablets was determined. 
Friability: The Roche friability test apparatus was used 
to determine the friability of the Tablets. Ten pre-
weighed Tablets were placed in the apparatus and was 
rotated at 25 rpm for 4 minutes and then the Tablets were 
reweighed. The percentage friability was calculated 
according to the following formula. 
% friability was calculated as follows 
% Friability = (W1 – W2) x 100/W1 
Where W1 = Initial weight of the 10 tablets. 
W2 = Final weight of the10 tablets after testing.                            
Friability values below 1.0% are generally acceptable. 
Drug content (assay): 
Ten tablets were taken and powdered.  Powder 
equivalent to one tablet was taken and dissolved in 50 ml 
of 0.1N Hcl. The mixture was allowed to stand for 1 hr 
with intermittent sonication to ensure complete hydration 
of polymer and subsequent solubility of the drug. Then 
the volume was made up to 100ml. The mixture was 
filtered and 1ml of the filtrate was suitably diluted. The 
absorbance of solution was measured by using UV – 
Visible spectrophotometer (Elico, India) at 257 nm. Each 
measurement was carried out in triplicate and the 
average drug content in the floating tablet was 
calculated. 
Swelling index: From each formulation, one tablet was 
weighed and placed in a beaker containing 200 ml of 
0.1N Hcl buffer solution. After each hour the tablet was 
removed from beaker and weighed. The percentage 
weight gain by the tablet was caluculated by using the 
formula. 
 
%SI =        Wt – W0      X 100 
W0 
%SI = Swelling index 
Wt = weight of tablet at time t 
W0= weight of tablet before immersion. 
In vitro floating lag time: 
The in vitro buoyancy was determined by floating lag 
time. The tablets were placed in a 100 ml beaker 
containing 0.1 N HCl. The media was kept in stagnant 
condition and the temperature was maintained at 370C. 
The time required for the tablet to rise to the surface and 
float was determined as floating lag time. 
In vitro floating duration time: 
The floating capacity of the tablets was determined using 
USP dissolution apparatus II containing 900 ml of 0.1 N 
Hcl. The time interval between introduction of the tablet 
into the dissolution medium and its buoyancy to the 
dissolution medium was taken as buoyancy lag time and 
for which time the tablet constantly floats on the surface 
of the medium was observed visually and taken as 
floating duration. 
In vitro Dissolution studies: 
The release of cephalexin from floating tablets was 
determined by using Dissolution type II test apparatus. 
The dissolution test was performed using 900 ml 0.1N 
Hcl solution at 37± 0.50C temperature and at 50 rpm.  At 
specified time intervals, samples of 5ml were withdrawn 
at predetermined time intervals (1 to 12hrs) and the same 
volume was replaced with fresh medium to maintain the 
volume constant.  The samples were filtered through 
Whattman filter paper  and  diluted to suitable 
concentration with 0.1N Hcl. The absorbance value of 
the diluted sample was analyzed by UV 
spectrophotometer at 257 nm. The percentage drug 
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release was calculated using an equation obtained from 
standard curve. 
Drug release kinetics and mechanism 
12,13,14,15
: 
To analyze the mechanism of drug release from the 
formulation, the dissolution profile of all the batches 
were fitted to zero order, first order, Higuchi and Peppas 
models to ascertain the kinetic modelling of drug release. 
 
Model Equation 
Zero order Q = K0 t 
First order Log Qt = Log Qo+ K1t / 2.303 
Korsmeyer-
Peppas model 
Mt/M∞ = ktn 
Higuichi Q = K2 t
1/2 
 
Similarity Factor (f2) Analysis: 
In vitro release profiles of floating tablets were compared 
with the theoretical release profile which was calculated 
earlier. The data were analyzed by the following 
formula. 
f2 = 50 log {[1+ (1/N) ∑ (Ri – Ti)
 2 ]-0.5 x 100} 
Where N = number of time points,  
Ri and Ti = dissolution of reference and test products at 
time i. 
 If f2 is greater than 50 it is considered that 2 products 
share similar drug release behaviors. 
 
Fourier Transform infrared (FTIR) Spectroscopic 
studies: 
Fourier Transform Infrared spectrophotometer (FTIR) 
was used for infrared analysis of samples to intercept the 
interactions of drug with polymers and other ingredients. 
FTIR studies were conducted for characterization of drug 
in tablets. The floating tablets were compressed and 
powdered.  The pelletized powder along with KBr was 
used for FTIR studies.  The IR spectra were recorded 
using Fourier Transform Infrared Spectrophotometer. 
The samples were analyzed between the wave numbers 
4000 and 400 cm2 . 
RESULT & DISCUSSION: 
RESULTS: 
 
Table 2: Results for Derived and Flow properties 
 
Formulation 
Code 
Derived properties Flow properties 
Bulk density 
(mean±SD) 
Tapped density 
(mean±SD) 
Angle of repose 
(mean±SD) 
Carr’s index 
(mean± 
        SD) 
Hausner’s ratio 
(mean±SD) 
F1 0.64±0.02 0.80±0.02 29.13±0.04 11.44±1.9 1.129±0.02 
F2 0.65±0.02 0.78±0.03 27.31±0.03 13.22±1.9 1.126±0.03 
F3 0.64±0.01 0.78±0.02 28.26±0.01 11.86±3.9 1.135±0.05 
F4 0.63±0.08 0.77±0.05 28.28±1.50 14.48±1.8 1.105±0.02 
F5 0.68±0.04 0.82±0.03 29.01±1.04 12.65±2.2 1.145±0.03 
F6 0.64±0.03 0.79±0.02 26.87±2.0 9.32±3.16 1.103±0.04 
F7 0.63±0.05 0.78±0.07 27.48±1.05 13.54±1.1 1.184±0.02 
F8 0.67±0.08 0.81±0.02 28.15±1.53 11.69±3.6 1.126±0.05 
F9 0.66±0.02 0.79±0.06 28.44±1.25 10.87±2.8 1.113±0.04 
F10 0.62±0.06 0.75±0.08 27.57±0.82 14.21±1.1 1.165±0.01 
F11 0.67±0.05 0.80±0.02 28.26±0.01 13.47±2.4 1.156±0.03 
F12 0.65±0.02 0.79±0.02 29.01±1.04 14.23±3.2 1.154±0.02 
F13 0.64±0.01 0.82±0.03 26.87±2.0 13.21±2.3 1.123±0.03 
F14               0.68±0.04 0.78±0.02 27.48±1.05 9.32±3.1 1.156±0.03 
F15 0.67±0.08 0.81±0.02 29.13±0.04 10.87±2.8 1.184±0.02 
F16 0.66±0.02 0.75±0.08 28.15±.53 14.21±1.1 1.135±0.05 
*** all values are expressed as mean± SD, n=3 
 
Hussain et al                                      Journal of Drug Delivery & Therapeutics; 2014, 4(1), 22-30    26 
Table 3:   Evaluation of physical parameters of the Tablets 
Formulation 
code 
Weight 
Variation(mg) 
 
Hardness 
(Kg/cm
2 
) 
 
Thickness 
(mm) 
 
Fraibility 
(%) 
 
Drug content 
(%) 
 
F1 549.5±3.80 5.83±0.28 5.38±0.06 0.66±0.03 97.4±0.5 
F2 549.4±2.79 6.66±0.28 5.27±0.12 0.79±0.04 100±2.5 
F3 548.8±3.58 6.83±0.28 5.41±0.09 0.26±0.03 104.8±1.17 
F4 550.5±3.02 6.0±0.5 5.28±0.09 0.40±0.05 104±0.2 
F5 549.5±3.84 5.28±0.28 5.20±0.11 0.53±0.03 95.66±0.08 
F6 550.4±2.71 6.5±0.5 5.28±0.12 0.94±0.01 99.14±1.02 
F7 550.4±3.29 6.1±0.3 5.26±0.17 0.26±0.02 100.88±2.51 
F8 548.9±4.40 6.1±0.7 5.28±0.12 0.60±0.04 100±2 
F9 549.8±4.13 7.83±0.28 5.23±0.14 0.66±0.03 103.4±3.32 
F10 548.8±3.52 7.5±0.61 5.25±0.14 0.40±0.05 101.7±0.01 
F11 549.4±4.51 7.5±0.86 5.26±0.15 0.91±0.06 101.7±0.01 
F12 550.5±3.83 7.66±0.28 5.22±0.17 0.39±0.94 104.36±1.0 
F13 548.3±4.98 7.5±0.5 5.44±0.04 0.48±0.08 99.81±1.4 
F14 549.1±2.51 7.7±0.7 5.36±0.04 0.41±0.03 100.26±0.8 
F15 546.6±4.97 7.2±0.4 5.39±0.08 0.64±0.16 99.18±0.6 
F16 548.8±4.31 7.66±0.28 5.26±0.09 0.36±0.03 97.53±1.3 
 
Table 4: Floating time 
Formulation 
code 
Floating lag time 
(Sec) 
Total floating 
time (hrs) 
F1 45 >12 hrs 
F2 45 >12 hrs 
F3 55 >12 hrs 
F4 65 >12 hrs 
F5 65 >12 hrs 
F6 70 >12 hrs 
F7 70 >12 hrs 
F8 85 >12 hrs 
F9 45 >12 hrs 
F10 45 >12 hrs 
F11 50 >12 hrs 
F12 60 >12 hrs 
F13 65 >12 hrs 
F14 75 >12 hrs 
F15 70 >12 hrs 
F16 90 >12 hrs 
 
Table 5: Swelling index of cephalexin floating tablets 
 
 
 
 
 
 
Formulation code Swelling index (%) 
F1 85.09 
F2 92.92 
F3 99.09 
F4 100.9 
F5 92.85 
F6 87.9 
F7 82.26 
F8 81.47 
F9 87.68 
F10 91.5 
F11 110.5 
F12 95.06 
F13 90.5 
F14 106.5 
F15 92.5 
F16 88 
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Table 6: KINETICS DATA OF ALL FORMULATIONS 
ZERO ORDER 
KINETICS 
FIRST ORDER 
KINETICS 
HIGUCHI PEPPAS 
CODE R2  K0 R
2  K1 R
2  R2     n 
F1 0.9015 11.43 0.9636 0.465 0.9974 0.9960 0.558 
F2 0.9227 9.146 0.9677 0.327 0.9929 0.9977 0.591 
F3 0.8893 8.10 0.9336 0.349 0.9630 0.9351 0.757 
F4 0.9156 7.06 0.9708 0.231 0.9889 0.9632 0.566 
F5 0.8894 7.855 0.9566 0.396 0.9857 0.9840 0.568 
F6 0.8625 7.689 0.8998 0.325 0.964 0.9157 0.685 
F7 0.9477 7.66 0.9730 0.168 0.9880 0.9934 0.592 
F8 0.8884 6.67 0.9802 0.189 0.9942 0.9896 0.553 
F9 0.905 11.13 0.9644 0.243 0.9847 0.9157 0.607 
F10 0.9362 8.717 0.9419 0.193 0.9704 0.9924 0.798 
F11 0.9193 7.989 0.9868 0.240 0.9584 0.9483 0.839 
F12 0.9375 7.223 0.9911 0.196 0.9866 0.9889 0.596 
F13 0.9093 7.779 0.9848 0.299 0.9876 0.9880 0.600 
F14 0.935 7.507 0.9464 0.223 0.9801 0.9666 0.734 
F15 0.9270 7.500 0.9886 0.103 0.9917 0.9833 0.632 
F16 0.8856 7.05 0.9827 0.251 0.9854 0.9723 0.500 
 
 
Fig 1: Comparison of dissolution profiles of F1, F2 & F3 
 
Fig 2: Comparison of dissolution profiles of F4, F5& 
F6 
 
Fig 3: Comparison of dissolution profiles of F7 & F8 
 
Fig 4: Comparison of dissolution profiles of F9, F10 
& F11 
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Fig 5: Comparison of dissolution profiles of F12, F13 
& F14 
 
Fig 6: Comparison of dissolution profiles of F15 & 
F16
 
 
Fig 7: FTIR study of Cephalexin(drug). 
 
 
Fig 8: FTIR study of Cephalexin (drug) + HPMCK4M 
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Fig 9: FTIR study of Cephalexin (drug)+ HPMCK100M. 
 
DISCUSSION: 
The absorption maximum was found to be 257 nm when 
scanned between 200 to 400 nm in 0.1 N HCl by the UV-
Visible spectrophotometer. FTIR spectra revealed that 
there was no interaction between the drug and the 
polymers. 
Standard graph of Cephalexin was performed in 0.1 N 
Hcl and graph showed a good linearity with an r 2 value 
of 0.999. 
The Pre formulation studies were performed and the 
results were shown in the following table 2. Bulk density 
was found in the range of 0.62-0.68 g/cm3 and the tapped 
density between 0.75-0.82 g/cm3. Using these two 
density data compressibility index was calculated. The 
compressibility index was found between 9.32- 14.48 
and the compressibility flowability correlation data 
indicated a fairly good flowability of the blend. Angle of 
repose was found to be in the range of 26.87- 29.13 
indicating excellent flowability, hausner’s ratio in range 
of 1.10- 1.16 indicating good flowability. The results 
were shown in table no.02 
The tablets of different formulations were subjected to 
various evaluation tests such as weight variation, 
hardness, thickness, friability and drug content. In weight 
variation test, the pharmacopoeial limit of percentage 
deviation for the tablets of more than 324 mg is ±5 %. 
The average percentage deviation of all the formulations 
were found to be within the limits. The hardness ranged 
from 5.8± 0.28 to 7.83± 0.28 kg/cm2 . The thickness of 
tablets ranged from 5.22± 0.17 to 5.44 ± 0.04 mm. The 
friability was below 1% for all the formulations, which is 
an indication of good mechanical resistance of the 
tablets. The drug content was found to be uniform in all 
formulations and ranged from 95.66 ± 0.08 to 104.8 ± 
1.17. The values were shown in table no. 03. 
The floating lag time was ranged from 45-90 sec and all 
the formulations showed good floating buoyancy time 
for more than 12 hrs. The results were shown in table no. 
04. 
Swelling index was performed for all the formulations 
(F1 to F16) up to 8 hours. The results of swelling index 
were shown in Table no. 05. The swelling index was 
calculated with respect to time. As time increases, the 
swelling index was increased because weight gain by 
tablet was increased proportionally with rate of 
hydration, later on, it decreased gradually due to 
dissolution of outermost gelled layer of tablet into 
dissolution medium. 
From the above results it was concluded that swelling 
index increases as the concentration of polymer 
increased, it was also observed that the maximum 
swelling attained in 8 hr, afterwards polymer slowly 
started erosion in the medium. 
In the present study, F11 formulation has shown 
maximum swelling index of   110.5%. 
FTIR studies revealed that there was no interaction. 
In Vitro dissolution studies of  all the formulations  were 
carried out in 0.1N HCl for 12hrs. All the floating 
formulations containing HPMC K4M (F1-F3) showed 
the drug release in controlled manner without changing 
their physical integrity in dissolution medium 
Formulations F1- F3 retarded the drug release as a 
function of polymer concentration. HPMC K4M, a 
hydrophilic polymer upon contact with aqueous fluid is 
able to form quite viscous gel, and hence retard the drug 
release from hydrophilic matrix. The percentage of drug 
release from the formulation F1 at the end of 8hrs is 
100%. The percentage of drug release from the 
formulation F2 at the end of 10hrs is 99.95%. The 
percentage of drug release from the formulation F3 at the 
end of 12hrs is 99.92%. As the concentration of polymer 
is increased the release rate of drug was decreased . 
Theoretically speaking this behaviour is expected since 
more amount of polymer always delays the release. 
Formulations F4 to F6 retarded the drug release as a 
function of polymers concentration. The percentage of 
drug released from the formulations F4, F5 & F6 at the 
end of 12 hrs is 94.16, 100, 100 respectively. 
Formulations F7 & F8  also retarded the drug release as a 
function of polymers concentration. The percentage of 
drug released from the formulation F7& F8 at the end of 
12 hrs is 100% & 96.12% respectively. All the floating 
formulations containing HPMC K100M (F9-F11) 
showed the drug release in controlled manner without 
changing their physical integrity in dissolution medium. 
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HPMC K100M, a hydrophilic polymer upon contact with 
aqueous fluid is able to form quite viscous gel, and hence 
retard the drug release from hydrophilic matrix. The 
maximum percentage of drug release from the 
formulation F9, F10 & F11 were 100% (10 hr), 100% 
(12 hr), and 94.16(12 hr) respectively. As the 
concentration of polymer is increased the release rate of 
drug was decreased. Theoretically speaking this 
behaviour is expected since more amount of polymer 
always delays the release. Formulations F12 to F14 
retarded the drug release as a function of polymers 
concentration. The maximum percentage of drug 
released from the formulations F12, F13 & F14  at the 
end of 12 hrs is 90, 97.16 & 95.04 respectively. 
Formulations F15 & F16 also retarded the drug release as 
a function of polymers concentration. The percentage of 
drug released from the formulation F15& F16at the end 
of 12 hrs is 97.38% & 96 % respectively.                     . 
The data obtained from in vitro dissolution studies were 
fitted to Zero order, first order, Higuchi and Korsemeyer 
peppas equation and the results are shown in Table 
no.06. The first order plots of all the formulations (F1-
F16) were found to be fairly linear as indicated by their 
high regression values when compared with zero order 
plots, so all these formulations followed first order 
kinetics. 
All  the formulations (F1- F16) showed good correlation 
in Higuchi Kinetics, clearly indicating that the drug 
release mechanism was predominantly diffusion 
controlled. To confirm the exact mechanism of drug 
release from these tablets, the data were fitted to 
Korsemeyer equation. The slope values suggested that 
the release of cephalexin from formulations (F1- F16 
)followed non fickian diffusion (n>0.50). 
CONCLUSION:  
In conclusion, different swelling polymers such as 
HPMC K100M, HPMC K4M individually and  in 
combination with, other polymers such as Xanthan gum, 
Guar gum, karaya gum, Sodium CMC and Ethyl 
cellulose can be successfully employed in the preparation 
of sustained release floating tablets of cephalexin. When 
compared to HPMC K4 M  HPMC K100M showed more 
sustained action when used individually or in 
combination.The research study provided useful 
information for the  scientists on formulation, 
characterization during development of controlled drug 
delivery systems of cephalexin using these polymers. 
The prepared formulations can be successfully 
commercialized after establishing the safety and efficacy 
in human volunteers. 
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